Dexcom (DXCM) FY2015 results: revenue $402 million, up 55.1% on the year
Dexcom Inc. (DXCM) reported revenue of $402 million for fiscal 2015, the year ended 31 December 2015, up 55.1% on the year before. Net income was -$58 million, and diluted earnings per share $-0.72. The figures are the company's own, from the 10-K it filed with the SEC on 23 February 2016.
Revenue
$402 million
+55.1% on the year
FY2009FY2015
Operating margin
-14.2%
-8.3% a year earlier
FY2009FY2015
Net income
-$58 million
FY2009FY2015
Diluted EPS
-$0.72
FY2009FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
402
259
160
+55.1%
Cost of revenue
124
82.9
59.9
+49.1%
Gross profit
278
176
100
+57.9%
Gross margin
69.3%
68.0%
62.6%
Research and development
138
69.4
44.8
+98.1%
Selling, general and administrative
198
128
84.2
+54.2%
Operating income
-57.1
-21.5
-28.9
Operating margin
-14.2%
-8.3%
-18.1%
Interest expense
0.4
0.8
0.9
-50.0%
Pre-tax income
-57.5
-22.3
-29.8
Income tax
0.1
0.1
0.0
0.0%
Net income
-57.6
-22.4
-29.8
Net margin
-14.3%
-8.6%
-18.6%
Diluted EPS
-$0.72
-$0.30
-$0.42
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
49.0
23.6
2.4
+107.6%
Capital expenditure
33.3
16.2
7.9
+105.6%
Free cash flow
15.7
7.4
-5.5
+112.2%
Free cash flow margin
3.9%
2.9%
-3.4%
Cash from investing
-51.5
-16.8
20.9
Cash from financing
16.8
21.8
11.8
-22.9%
Depreciation and amortisation
10.8
8.4
7.0
+28.6%
Share-based compensation
82.7
50.0
24.6
+65.4%
Shares outstanding at period end
82m
77m
72m
+5.7%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
221
140
84.1
+57.8%
Debt
2.3
4.6
6.8
-50.0%
Other liabilities
68.5
39.8
31.6
+72.1%
Total liabilities and equity
292
185
122
+58.2%
Fixed assets
54.7
31.2
20.7
+75.3%
Goodwill
3.7
3.2
3.2
+15.6%
Intangible assets
2.2
2.7
3.6
-18.5%
Investments
29.1
11.8
11.4
+146.6%
Cash and equivalents
86.1
71.8
43.2
+19.9%
Receivables
74.1
42.4
n/a
+74.8%
Inventory
35.2
16.0
9.0
+120.0%
Other assets
6.9
5.5
31.4
+25.5%
Total assets
292
185
122
+58.2%
10-K for the year ended 31 December 2015, filed 23 February 2016: the filing.